龍利得(300883.SZ):深交所同意公司撤回發行可轉債的申請文件
格隆匯1月20日丨龍利得(300883.SZ)公佈,近日,公司收到深交所出具的《關於終止對龍利得智能科技股份有限公司申請向不特定對象發行可轉換公司債券審核的決定》(深證上審〔2022〕15號),根據《深圳證券交易所創業板上市公司證券發行上市審核規則》第十九條、《深圳證券交易所創業板股票發行上市審核規則》第六十七條的有關規定,深交所決定終止對公司申請向不特定對象發行可轉換公司債券事項的審核。
此次撤回可轉債申請文件不會影響公司龍利得(河南)綠色智能文化科創園項目的正常實施,公司將根據中國證監會和深交所的相關規定擇機推進資本市場再融資方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.